Allergan is buying Motus Therapeutics, a subsidiary of Rhythm Holding designed to hold its diabetic gastroparesis treatment relamorelin, under an option deal…
ProQR Therapeutics saw its stock surge on the back of data from a small clinical trial of its cystic fibrosis drug QR-010.
Leading manufacturers increasingly employ stakeholder research early in development to better identify the needs of patients and providers. Learn how this…
DBV posts peanut allergy data, TiGenix looks to file for an IPO, Oasmia is buying a cancer drug and more.
In our EuroBiotech roundup this week, NeuroVive closes its Lyon subsidiary, ObsEva misses a primary endpoint, Active Biotech offloads a cancer drug, and more.
TiGenix has dusted off its plan to file for an IPO on Nasdaq and brought in a new set of underwriters.
It has discontinued lead Phase IIb maturation inhibitor BMS-955176, which it bought from BMS, and COPD candidate losmapimod.
Biogen is aggressively pursuing neurodegenerative diseases, such as spinal muscular atrophy and Alzheimer’s disease.
Genomics Medicine Ireland has raised $40 million in a Series A round to create a genomic R&D program based in Dublin.
An IPO for Ra Pharmaceuticals has priced raising $92 million, while another for Myovant Sciences has commitments from Pfizer and BB Biotech.
Verona Pharma has secured funding for a Phase IIa trial of its PDE3/PDE4 inhibitor RPL554 in cystic fibrosis patients.